Identification of predictors of response to Erenumab in a cohort of patients with migraine

Background: The migraine-specific monoclonal antibody Erenumab targeting the calcitonin gene related peptide receptor is an effective and well tolerated preventive treatment of episodic chronic migraine. However, its price limits use as a first line therapy against Therefore, identifying patients who will adequately respond to such paramount. Methods: In this retrospective, real-life cohort study, 172 adult with refractory or migraine treated were included. To identify predictors response Erenumab, bivariate subgroup analysis several potential factors was performed, multivariate logistic regression modeling done obtain Odds Ratio (OR). Results: Of patients, 57.0% achieved successful (reduction monthly days by ?50%). Statistically significant presence migraine, tension-type headache, positive triptan odd ratio 0.473 (95% CI, 0.235–0.952), 0.485 0.245–0.962) 3.985 1.811–8.770), respectively (P < 0.05). Conclusions: Successful rate in retrospective cohort. As headache negative while predictor, data suggests for monotherapy without need traditional sufferers improving side effect profile adherence difficult treat.